A polymorphism in the OPRM1 3′-untranslated region is associated with methadone efficacy in treating opioid dependence
RC Crist, GA Doyle, EC Nelson, L Degenhardt… - The …, 2018 - nature.com
The pharmacogenomics journal, 2018•nature.com
The μ-opioid receptor (MOR) is the primary target of methadone and buprenorphine. The
primary neuronal transcript of the OPRM1 gene, MOR-1, contains a~ 13 kb 3′ untranslated
region with five common haplotypes in European-Americans. We analyzed the effects of
these haplotypes on the percentage of opioid positive urine tests in European-Americans
(n= 582) during a 24-week, randomized, open-label trial of methadone or buprenorphine/
naloxone (Suboxone) for the treatment of opioid dependence. A single haplotype, tagged by …
primary neuronal transcript of the OPRM1 gene, MOR-1, contains a~ 13 kb 3′ untranslated
region with five common haplotypes in European-Americans. We analyzed the effects of
these haplotypes on the percentage of opioid positive urine tests in European-Americans
(n= 582) during a 24-week, randomized, open-label trial of methadone or buprenorphine/
naloxone (Suboxone) for the treatment of opioid dependence. A single haplotype, tagged by …
Abstract
The μ-opioid receptor (MOR) is the primary target of methadone and buprenorphine. The primary neuronal transcript of the OPRM1 gene, MOR-1, contains a~ 13 kb 3′ untranslated region with five common haplotypes in European-Americans. We analyzed the effects of these haplotypes on the percentage of opioid positive urine tests in European-Americans (n= 582) during a 24-week, randomized, open-label trial of methadone or buprenorphine/naloxone (Suboxone) for the treatment of opioid dependence. A single haplotype, tagged by rs10485058, was significantly associated with patient urinalysis data in the methadone treatment group. Methadone patients with the A/A genotype at rs10485058 were less likely to have opioid-positive urine drug screens than those in the combined A/G and G/G genotypes group (relative risk= 0.76, 95% confidence intervals= 0.73–0.80, P= 0.0064). Genotype at rs10485058 also predicted self-reported relapse rates in an independent population of Australian patients of European descent (n= 1215) who were receiving opioid substitution therapy (P= 0.003). In silico analysis predicted that miR-95-3p would interact with the G, but not the A allele of rs10485058. Luciferase assays indicated miR-95-3p decreased reporter activity of constructs containing the G, but not the A allele of rs10485058, suggesting a potential mechanism for the observed pharmacogenetic effect. These findings suggest that selection of a medication for opioid dependence based on rs10485058 genotype might improve outcomes in this ethnic group.
nature.com
以上显示的是最相近的搜索结果。 查看全部搜索结果